NCT05838274 Acute Alcohol Response In Bipolar Disorder: a Longitudinal Alcohol Administration/fMRI Study
| NCT ID | NCT05838274 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Texas at Austin |
| Condition | Bipolar Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-07-11 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2023-07-11 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Alcohol use disorders (AUDs) affect up to 60% of individuals with bipolar disorder during their lifetime and is associated with worse illness outcomes, yet few studies have been performed to clarify the causes of this comorbidity. Understanding biological risk factors that associate with and predict the development of AUDs in bipolar disorder could inform interventions and prevention efforts to reduce the rate of this comorbidity and improve outcomes of both disorders. Identifying predictors of risk requires longitudinal studies in bipolar disorder aimed at capturing the mechanisms leading to the emergence of AUDs. Previous work in AUDs suggest that subjective responses to alcohol and stress-related mechanisms may contribute to the development of AUDs. In bipolar disorder, altered developmental trajectory of critical ventral prefrontal networks that modulate mood and reward processing may alter responses to alcohol and stressors; consequently, the disruption in typical neurodevelopment may be an underlying factor for the high rates of comorbidity. No longitudinal data exist investigating if this developmental hypothesis is correct. To address this gap, the investigators will use a multimodal neuroimaging approach, modeling structural and functional neural trajectories of corticolimbic networks over young adulthood, incorporating alcohol administration procedures, clinical phenotyping, and investigating effects of acute stress exposure and early life stress. Research aims are to identify biological risk factors-i.e., changes in subjective response to alcohol and associated neural trajectories-that are associated with the development of alcohol misuse and symptoms of AUDs over a two-year longitudinal period in young adults with bipolar disorder and typical developing young adults. Longitudinal data will be collected on 160 young adults (50% with bipolar disorder, 50% female; aged 21-26). This study is a natural extension of the PI's K01 award. How acute exposure to stress and childhood maltreatment affects subjective response to alcohol and risk for prospective alcohol misuse and symptoms of AUDs will be investigated. The investigators will test our hypothesis that developmental differences in bipolar disorder versus typical developing individuals disrupt corticolimbic networks during young adulthood, increase sensitivity to stress, and lead to changes in subjective response to alcohol and placebo response increasing risk for developing AUDs.
Eligibility Criteria
Inclusion Criteria: Inclusion criteria for all participants: * between 21 and 26 years of age * having consumed at least 4 (men) or 3 (women) drinks on a single occasion over the last year * euthymic at the time of enrollment Inclusion criteria for bipolar disorder participants: \- Meeting Diagnostic and Statistical Manual-5 Research Version (DSM-V-RV) diagnostic criteria for bipolar disorder, confirmed by structured interview Exclusion Criteria: For all subjects exclusion criteria include: * history of significant medical illness, particularly if possible changes in cerebral tissue * neurologic abnormality including significant head trauma (loss of consciousness of ≥5-min) * full Scale intelligence quotient (IQ) \<85 * contraindication to MRI scanning * positive pregnancy test * current cannabis use disorder\>moderate * history of severe AUDs * scores \> 15 on the alcohol Use Disorders Identification Test (AUDIT; part of phone screen) * ever being in an abstinence-oriented treatment program for alcohol use * reporting wanting to quit drinking but not being able to * any medical, religious, or other reasons for not drinking alcohol * history of heart attack, heart trouble, high blood pressure, diabetes, or liver disease * an adverse reaction to alcoholic beverages * reporting never consuming 4 (men) or 3 (women) or more drinks on a single occasion over the last year * unwillingness to have a friend or family member drive them home after the alcohol administration sessions * a past year substance use disorder (other than alcohol, cannabis, or nicotine) Additional exclusion criteria for bipolar disorder participants: \- not taking medications for greater than or equal to 4 weeks (i.e. participants must be stable on medications) Additional exclusion criteria for healthy comparison subjects also include: * any prior psychiatric hospitalizations * lifetime history of a neurodevelopmental disorder, affective disorder, psychotic disorder, eating disorder * greater than 1 month of lifetime psychotropic medication.
Contact & Investigator
Elizabeth Lippard, PhD
PRINCIPAL INVESTIGATOR
University of Texas at Austin
Frequently Asked Questions
Who can join the NCT05838274 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 26 Years, studying Bipolar Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05838274 currently recruiting?
Yes, NCT05838274 is actively recruiting participants. Contact the research team at behavioral.neuroimaging@austin.utexas.edu for enrollment information.
Where is the NCT05838274 trial being conducted?
This trial is being conducted at Austin, United States.
Who is sponsoring the NCT05838274 clinical trial?
NCT05838274 is sponsored by University of Texas at Austin. The principal investigator is Elizabeth Lippard, PhD at University of Texas at Austin. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.